-- Company Expects to Deliver Topline Immunogenicity Results from the Phase 1/2 Clinical Study by End of 2022 -- -- VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Candidate Designed to Provide Broad-Spectrum Protection -- SAN CARLOS, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc.